Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest System. Products are sold through home-care, institutional, government and international channels.
The filing covers the three- and nine-month periods ended March 31, 2012, Electromed’s fiscal third quarter and first nine months of fiscal 2012. The filing is unaudited. The requested “2011 Q3” label does not match the filing’s stated reporting period.
Financial Performance and Key Metrics
| Metric | Three Months Ended March 31, 2012 | Three Months Ended March 31, 2011 | Nine Months Ended March 31, 2012 | Nine Months Ended March 31, 2011 |
|---|---|---|---|---|
| Net revenues | $4.774 million | $5.199 million | $14.944 million | $14.050 million |
| Gross profit | $3.369 million | $3.703 million | $10.919 million | $10.177 million |
| Gross margin | 70.6% | 71.2% | 73.1% | 72.4% |
| Operating income | $226 thousand | $672 thousand | $778 thousand | $1.462 million |
| Net income | $95 thousand | $487 thousand | $365 thousand | $891 thousand |
| Net margin | 2.0% | 9.4% | 2.4% | 6.3% |
| Diluted EPS | $0.01 | $0.06 | $0.04 | $0.12 |
For the nine months, home-care revenue increased 8.3% to $13.790 million, while international revenue declined 21.2% to $395 thousand and government/institutional revenue declined 6.4% to $759 thousand. In the quarter, home-care revenue declined 7.0%, international revenue increased 15.4%, and government/institutional revenue declined 32.2%.
Nine-month SG&A expense increased 17.6% to $9.435 million, primarily from higher staffing and related compensation. Research and development expense increased 2.5% to $706 thousand, representing 4.7% of revenue; management expects to spend at least 5.0% of sales on research and development for the foreseeable future.
Cash Flow, Balance Sheet, Debt and Liquidity
- Cash and cash equivalents were $1.393 million at March 31, 2012, down from $4.092 million at June 30, 2011.
- Operating activities used $1.679 million during the first nine months of fiscal 2012, compared with $1.276 million used in the prior-year period. Working-capital uses included increases of $1.498 million in accounts receivable and $556 thousand in inventories.
- Investing activities used $761 thousand, including $736 thousand for property and equipment and $25 thousand for patent-related costs.
- Financing activities used $258 thousand, including approximately $299 thousand of principal payments on long-term debt.
- Total debt outstanding under the U.S. Bank facility was approximately $3.453 million at March 31, 2012, consisting of $1.768 million drawn on the revolving line and approximately $1.685 million of term debt.
- The revolving facility provides up to $6.0 million, subject to borrowing-base limitations. Net unused availability was approximately $3.435 million at March 31, 2012. The facility expires December 31, 2013, unless renewed earlier.
- Total assets were $20.821 million and total liabilities were $5.601 million at March 31, 2012. The company reported compliance with its credit-facility requirements as of that date.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue declined 8.2%, primarily because of lower home-care and government/institutional sales. Management attributed the home-care decline partly to sales-force turnover and fewer experienced Clinical Area Managers.
- Nine-month revenue increased 6.4%, driven by higher home-care sales and a larger sales force, but the increase did not translate into higher earnings.
- Quarterly gross margin decreased to 70.6% from 71.2% because of a less favorable reimbursement mix. Nine-month gross margin increased to 73.1% from 72.4% because of higher-than-average reimbursement mix.
- Quarterly operating income fell 66.4% and quarterly net income fell 80.5%. Nine-month operating income declined 46.8% and net income declined 59.0%, reflecting increased SG&A investment, sales-force turnover and a higher effective tax rate.
- The nine-month effective tax rate increased to 43.7% from 32.0%, partly because of changes in permanent differences and uncertainty regarding extension of the federal research and development tax credit.
- Capital spending increased to $736 thousand from $315 thousand, including $439 thousand for conversion of approximately 10,000 square feet of a newly leased office facility.
Outlook, Risks, Contingencies and Unusual Items
- Management believes existing cash and available borrowing capacity will provide adequate liquidity for the next year, but stated that additional financing may not be available on favorable terms, or at all, if operating performance or capital needs require it.
- Management expects continued investment in sales, reimbursement, patient services and research and development to support future growth. No specific revenue or earnings guidance was provided.
- International sales remain subject to global economic conditions, including the European sovereign debt situation and related austerity measures. Management cautioned that the quarterly increase in international sales was not necessarily indicative of a trend.
- Key risks include reimbursement changes involving Medicare, Medicaid and private insurers; regulatory compliance and approvals; sales-force recruitment and retention; competition; international expansion; intellectual-property protection; litigation; credit-market conditions; and general economic conditions.
- The former Chairman and Chief Executive Officer retired effective May 11, 2012. Dr. James Cassidy was appointed interim Chief Executive Officer. The leadership change triggered a credit-agreement covenant violation and potential event of default, which U.S. Bank waived on May 14, 2012.
- The separation arrangement with the former CEO provides for approximately $209 thousand of salary continuation, an estimated $98 thousand of earned bonus and estimated COBRA payments of $16.5 thousand, subject to the agreement’s terms.
- The company’s prior Hill-Rom trademark litigation was settled in 2010 without a material impact, and the company expects to continue using the SmartVest marks. The filing states that no undisclosed litigation is expected to have a material adverse effect.
- The company disclosed related-party arrangements involving research and development services and a parts supplier associated with company directors or management.
- No off-balance-sheet arrangements were reported. Disclosure controls and procedures were considered effective, with no material changes to internal control during the quarter.
Important Facts for Investors to Verify
- Whether sales-force stabilization and increased staffing convert into sustained home-care revenue growth and improved operating leverage.
- Accounts-receivable collection trends, inventory growth and the company’s ability to generate positive operating cash flow.
- Availability under the revolving facility after applying the borrowing-base limitation and the scheduled December 2012 maturity of Term Loan B.
- Compliance with the amended credit agreement following the CEO transition and the terms of the May 14, 2012 waiver.
- The sustainability of reimbursement rates and gross margins, particularly given Medicaid exposure and referral mix.
- The final costs and accounting treatment of executive separation arrangements and any future CEO transition.
- International demand trends and the effects of economic conditions on European and other overseas sales.